ASPM, CENPF and TRIP13 are Potential Diagnostic Markers and Therapeutic Targets for Lung Adenocarcinoma

Pengfei Lyu, Hao Qin, Yan Wang, Pingming Fan and Siyuan Dong

Background and Objective: Lung adenocarcinoma (ADC) is a main subtype comprising nearly 50% of all lung cancer cases with high resistant rate and poor treatment. However, the mechanism is still unclear. In this research, bioinformatics was used to explore hub genes which closely associated with the pathogenesis of lung ADC to confirm novel diagnostic biomarkers and therapeutic targets. Materials and Methods: GEO database was used to screen differentially expressed genes (DEGs), then hub genes were clustered by Cytoscape. Biological function of hub genes was analyzed by database including DAVID and GEPIA. Furthermore, TCGA database was applied to confirmed expression of hub genes with relevant clinical data. Moreover, the Connectivity Map (CMap) was performed to explore potential molecule compounds which aim to reverse the expression of hub genes. Results: Hub genes including ASPM, CENPF and TRIP13 over expressed in solid tumors of lung ADC and recurrent tumors, compared with normal tissues. Especially, these three genes showed high mutation rate in lung ADC. As well, they were over expressed in the fourth stage of lung ADC, which were associated with overall survival and disease-free survival in lung ADC patients. Small molecules including phenoxybenzamine, adiphenine and resveratrol were predicted to reverse expression of ASPM, CENPF and TRIP13. Conclusion: ASPM, CENPF and TRIP13 may be the potential diagnostic biomarkers and therapeutic targets for lung ADC.

View Fulltext Back